CA1200494A - Process of producing composition for long acting nicardipine preparation - Google Patents
Process of producing composition for long acting nicardipine preparationInfo
- Publication number
- CA1200494A CA1200494A CA000418228A CA418228A CA1200494A CA 1200494 A CA1200494 A CA 1200494A CA 000418228 A CA000418228 A CA 000418228A CA 418228 A CA418228 A CA 418228A CA 1200494 A CA1200494 A CA 1200494A
- Authority
- CA
- Canada
- Prior art keywords
- composition
- nicardipine
- mixture
- water
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 112
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 229960001783 nicardipine Drugs 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims description 23
- 238000000034 method Methods 0.000 title claims description 16
- 239000008188 pellet Substances 0.000 claims abstract description 39
- 239000003960 organic solvent Substances 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000654 additive Substances 0.000 claims abstract description 17
- 230000000996 additive effect Effects 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 230000001419 dependent effect Effects 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 14
- 238000005507 spraying Methods 0.000 claims abstract description 13
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 12
- 239000007921 spray Substances 0.000 claims abstract description 11
- 239000004094 surface-active agent Substances 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 abstract description 8
- 239000002245 particle Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 238000000576 coating method Methods 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000011369 resultant mixture Substances 0.000 description 5
- 239000011343 solid material Substances 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003139 Eudragit® L 100 Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- -1 polyoxyethylene Polymers 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- HHAVHBDPWSUKHZ-UHFFFAOYSA-N propan-2-ol;propan-2-one Chemical compound CC(C)O.CC(C)=O HHAVHBDPWSUKHZ-UHFFFAOYSA-N 0.000 description 2
- DWCNNQOORRREID-UHFFFAOYSA-N 1,2-dichloroethane;methanol Chemical compound OC.ClCCCl DWCNNQOORRREID-UHFFFAOYSA-N 0.000 description 1
- TZDPJNSHSWMCPN-UHFFFAOYSA-N 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid Chemical compound OC(=O)C1=C(C)NC(C)=C(C(O)=O)C1C1=CC=CC([N+]([O-])=O)=C1 TZDPJNSHSWMCPN-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000134884 Ericales Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000282337 Nasua nasua Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960002289 nicardipine hydrochloride Drugs 0.000 description 1
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPSN108608/81 | 1981-12-23 | ||
| JP56208608A JPS58116414A (ja) | 1981-12-23 | 1981-12-23 | ニカルジピン持続性製剤用球形顆粒およびその製造法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1200494A true CA1200494A (en) | 1986-02-11 |
Family
ID=16559022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000418228A Expired CA1200494A (en) | 1981-12-23 | 1982-12-21 | Process of producing composition for long acting nicardipine preparation |
Country Status (8)
| Country | Link |
|---|---|
| KR (1) | KR860001147B1 (enrdf_load_stackoverflow) |
| AT (1) | AT386743B (enrdf_load_stackoverflow) |
| CA (1) | CA1200494A (enrdf_load_stackoverflow) |
| ES (1) | ES518487A0 (enrdf_load_stackoverflow) |
| GR (1) | GR77096B (enrdf_load_stackoverflow) |
| IT (1) | IT1200966B (enrdf_load_stackoverflow) |
| MX (1) | MX7567E (enrdf_load_stackoverflow) |
| PT (1) | PT76023B (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806361A (en) * | 1984-06-04 | 1989-02-21 | Sterling Drug Inc. | Medicaments in sustained release unit dose form |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2117571C3 (de) * | 1971-04-10 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
| EP0001247A1 (en) * | 1977-09-14 | 1979-04-04 | Kanebo, Ltd. | Pharmaceutical preparation containing nifedipine and a method for producing the same. |
| CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
-
1982
- 1982-12-16 MX MX82101116U patent/MX7567E/es unknown
- 1982-12-20 AT AT0460682A patent/AT386743B/de not_active IP Right Cessation
- 1982-12-21 CA CA000418228A patent/CA1200494A/en not_active Expired
- 1982-12-21 GR GR70132A patent/GR77096B/el unknown
- 1982-12-22 ES ES518487A patent/ES518487A0/es active Granted
- 1982-12-22 IT IT68503/82A patent/IT1200966B/it active Protection Beyond IP Right Term
- 1982-12-22 PT PT76023A patent/PT76023B/pt unknown
- 1982-12-23 KR KR8205782A patent/KR860001147B1/ko not_active Expired
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806361A (en) * | 1984-06-04 | 1989-02-21 | Sterling Drug Inc. | Medicaments in sustained release unit dose form |
| EP0164959B1 (en) * | 1984-06-04 | 1992-03-11 | Sterwin Ag. | Pharmaceutical composition in sustained release unit dose form and process for its preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| ES8402156A1 (es) | 1984-02-01 |
| AT386743B (de) | 1988-10-10 |
| PT76023A (en) | 1983-01-01 |
| MX7567E (es) | 1989-10-27 |
| IT8268503A0 (it) | 1982-12-22 |
| IT1200966B (it) | 1989-01-27 |
| KR860001147B1 (ko) | 1986-08-18 |
| PT76023B (en) | 1986-02-12 |
| ES518487A0 (es) | 1984-02-01 |
| ATA460682A (de) | 1988-03-15 |
| GR77096B (enrdf_load_stackoverflow) | 1984-09-06 |
| KR840002652A (ko) | 1984-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5093200A (en) | Multilayer sustained release granule | |
| US8217054B2 (en) | Use of polyols to obtain stable polymorphous forms of rifaximin | |
| EP1010423B1 (en) | Oral pharmaceutical preparation comprising an antiulcer benzimidazole derivative, and process for its production | |
| FI97690C (fi) | Lääkkeen vapautumista kontrolloiva koostumus | |
| CA1228815A (en) | Fast release solid preparation of dihydropyridine a compound | |
| US4758437A (en) | Composition for long acting nicardipine preparation and process of producing the composition | |
| HU198385B (en) | Process for producing peroral pharmaceutical compositions containing acid-sensitive benzimidazol derivatives for treating gastrointestinal illnesses | |
| AU674175B2 (en) | Oral compositions containing 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxyaldehyde-o- methyl-oxime | |
| KR20010074914A (ko) | 오메프라졸 제형 | |
| HK1043051A1 (en) | Controlled release bupropion formulation | |
| JP2009527554A (ja) | コハク酸メトプロロールｅ．ｒ．の錠剤およびその調製方法 | |
| EP1748764B1 (en) | An amine drug-containing slow-release granule preparation based on particles with a coating layer and the corresponding method of production | |
| JPS647047B2 (enrdf_load_stackoverflow) | ||
| JP2000053563A (ja) | 苦味がマスクされた速放性細粒剤 | |
| US5741507A (en) | Ranitidine tablet having a hydroxypropylmethylcellulose containing coating and a method for producing said coating | |
| CA1200494A (en) | Process of producing composition for long acting nicardipine preparation | |
| KR20070094627A (ko) | 비점착제와 함께 미분화된 장용 중합체를 포함하는 장용 막피복 조성물 | |
| EP0640341A1 (en) | Sustained release pharmaceutical composition and process for producing same | |
| US5258186A (en) | Drug release controlling coating material for long acting formulations | |
| JPH04264023A (ja) | 持続性カプセル製剤 | |
| KR100491647B1 (ko) | 알긴산 나트륨 피복층을 포함하는 벤즈 이미다졸 유도체의경구체제 및 그의 제조방법 | |
| HUT70759A (en) | Stabile pharmaceutical compositions containing ipsapiron having retard effect | |
| KR100396443B1 (ko) | 가용화된 펠로디핀 함유 지속성제제의 조성물 및 그의제조방법 | |
| JPS62263124A (ja) | 経口投与製剤 | |
| WO2005016317A1 (en) | Process for manufacture of extended release pellets containing diltiazem hci |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |